Your session is about to expire
← Back to Search
Vascular Closure Device
Mynx Control Venous Closure for Venous Vascular Closure (ReliaSeal Trial)
N/A
Waitlist Available
Research Sponsored by Cordis Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post procedure
Awards & highlights
Summary
This trial is testing a new device to see if it is better than manual compression to seal femoral access sites after endovascular procedures.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days post procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Primary Effectiveness Endpoint: Time to Ambulation
Primary Effectiveness Endpoint: Time to Hemostasis
Primary Safety Endpoint: Major Complications of the Target Limb Access Site Within 30 Days
Secondary outcome measures
Device Success
Procedural Success
Secondary Safety Endpoints: Minor Complications of the Target Limb Access Site Within 30 Days
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Mynx Control Venous ClosureExperimental Treatment1 Intervention
204 (2:1 randomized - 136 VCD:68 manual compression)
Group II: Manual CompressionActive Control1 Intervention
204 (2:1 randomized - 136 VCD:68 manual compression)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYNX CONTROL™ Venous Vascular Closure Device 6F-12F
2022
N/A
~360
Find a Location
Who is running the clinical trial?
Cordis CorporationLead Sponsor
91 Previous Clinical Trials
123,306 Total Patients Enrolled
NAMSAOTHER
49 Previous Clinical Trials
19,358 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger